US80105N1054 - ADR
48.6 -0.17 (-0.35%)
NASDAQ:SNY (2/26/2024, 9:42:50 AM)
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 91,573 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.
46 Avenue de la Grande Armee
Paris ILE-DE-FRANCE 75008
CEO: Paul Hudson
Sanofi and Regeneron's Dupixent receives priority review from FDA for its use in treating chronic obstructive pulmonary disease (COPD).
Dive into the compelling world of GRANOLAS stocks: Europe's elite players shaping the future of pharmaceuticals, tech, and consumer goods.
Regeneron (REGN) and Vertex Pharmaceuticals (VRTX) join the $100B market cap club in the biotech industry, outperforming their rivals last year. Read more here.
The FDA put studies in eczema and asthma treatment on clinical hold.
Sanofi's ADRs surge 3% as several prominent private equity firms express interest in its consumer health unit, per Bloomberg report.
Sanofi ADRs surge 3% as several prominent private equity firms express interest in its consumer health unit, per Bloomberg report.
Here you can normally see the latest stock twits on SNY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.